Health leaders agree Biden’s foot-dragging on finding a new director during a national health crisis has demoralized the staff and sent the wrong message about the agency’s importance.
Cognitive decline varies widely among people who have started experiencing memory and thinking problems or who are in the earliest stage of Alzheimer’s — the patients who received Aduhelm.
Scientists may have to wait many years to find out whether Aduhelm is actually effective because the drug was approved using FDA's accelerated pathway.
Prescriptions for a controversial new drug for Alzheimer's could run $56 billion a year, putting a significant financial burden on Medicare, the health insurance for the elderly.